TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX: 13 ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the New Drug ...

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial results for the ...

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM, HKEX:13), a biopharmaceutical company, today disclosed the upcoming retirement of two of its Independent Non-executive Directors, Mr Paul ...

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM: HCM; HKEX: 13), a commercial-stage biopharmaceutical company, announced today that its shareholders passed an ordinary resolution during an ...

Despite reporting lower-than-expected revenue for 2024, Hutchmed (NASDAQ:HCM) traded higher on Wednesday after the Chinese biotech announced that a Phase 2/3 trial for its cancer drug combo ...

Hutchmed reported 2024 earnings of $0.22 per ADS, down from $0.71 last year, with sales falling 25% to $630.2 million. FRUSICA-2 trial met its primary endpoint, supporting fruquintinib’s use in ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED”, the "Company” or "we”) (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial ...